

The Application of 2-Benzyl-1,4-naphthoquinones as Pronucleophiles in Aminocatalytic Synthesis of Tricyclic Derivatives

Anna Skrzyńska, Marta Romaniszyn, Dominika Pomikło, and Lukasz Albrecht

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.8b00170 • Publication Date (Web): 12 Apr 2018

Downloaded from <http://pubs.acs.org> on April 12, 2018

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



The Application of 2-Benzyl-1,4-naphthoquinones as Pronucleophiles in Aminocatalytic Synthesis of Tricyclic Derivatives


*Anna Skrzyńska,[‡] Marta Romaniszyn,[‡] Dominika Pomikło, and Łukasz Albrecht**

Institute of Organic Chemistry, Faculty of Chemistry, Lodz University of Technology,

Zeromskiego 116, 90-924 Łódź, Poland

RECEIVED DATE (to be automatically inserted after your manuscript is accepted if required according to the journal that you are submitting your paper to)

SYNOPSIS TOC




KEYWORDS: Asymmetric catalysis; Vinylogy; 1,4-Naphthoquinones; Naphthalen-1(4*H*)-ones; Remote functionalization.

ABSTRACT: This study demonstrates an unprecedented reactivity of 2-substituted-1,4-naphthoquinones. By applying the principle of vinylogy they have been employed as vinylogous

pronucleophiles in the organocatalytic cascade reaction for the first time. This novel catalytic activation of 1,4-naphthoquinones enables access to carboannulated naphthalen-1(4*H*)-one derivatives of biological importance. The site-selectivity and stereoselectivity of a process proved possible to control by the proper choice of reaction conditions.

Introduction

The development of methods for the facile and efficient construction of complex carbocyclic frameworks constitutes highly relevant goal in the contemporary organic chemistry.¹ In particular, the application of cascade reactivities involving C-C bond-forming event merged with subsequent reactions for the synthesis of bio-inspired products have received considerable interest in the past few years.² Among various privileged carbocyclic structures in organic chemistry, α -tetralone and naphthalen-1(4*H*)-one ring systems occupy a prominent position (Scheme 1, top). Due to the presence of a carbonyl group and a double bond within their structure they possess high synthetic usefulness correlated with the functionalization potential of these reactive moieties. Furthermore, such ring systems can be found in nature.^{3,4} For instance, Hamigerans are a family of natural products that contains a α -tetralone structural unit merged with additional five-membered cyclopentane ring (Scheme 1, bottom).⁴




Scheme 1. The importance of α -tetralone and naphthalen-1(4*H*)-one derivatives

1
2
3 1,4-Naphthoquinones and their 2-alkyl-substituted derivatives constitute a useful group of
4 reactants commonly employed in asymmetric synthesis.⁵ Due to the presence of a highly
5 electron-deficient double bond they can act as electrophiles in a Michael-type additions.^{5b-e}
6
7 Furthermore, they are employed as electron-poor dienophiles in various cycloaddition
8 reactions.^{5f-i} Surprisingly, to the best of our knowledge their potential as vinylogous
9 pronucleophiles in organic synthesis has never before been explored. In the context, it is worth to
10 note that the vinylogous reactivity of organic compounds constitutes a rapidly developing field in
11 the contemporary organic chemistry.^{6,7} Due to the presence of conjugated double bond system in
12 vinylogous reactants a transfer of electrophilic or nucleophilic character to a remote reaction site
13 is possible. In the past few years the principle of vinylogy has been successfully implemented in
14 the field of asymmetric organocatalysis.^{7,8} In such a manner new reaction pathways have been
15 identified opening access to a variety of optically active products relevant for life-science
16 industry.

17
18
19 Given the importance of carboannulated naphthalen-1(4*H*)-one derivatives and lack of
20 literature precedents on nucleophilic reactivity of 2-substituted-1,4-naphthoquinones **1**, the task
21 of development of such a reactivity for the synthesis of carboannulated naphthalen-1(4*H*)-ones **3**
22 has been undertaken. The novel reactivity concept is based on the application of dienolate **A**
23 readily available via deprotonation of 2-substituted-1,4-naphthoquinones **1** at the C-1' position.
24 We envisioned that deprotonation of **1** should be possible to realize under relatively mild, basic
25 conditions due to the efficient stabilization of **A** through resonance (Scheme 2, middle). It was
26 anticipated that such a system should be capable of participating in the cascade reaction
27 involving Michael addition from the C-1' position of **A** to the iminium-ion-activated enal **2**
28 followed by the intramolecular aldol condensation to give **3** (Scheme 2, bottom, cascade A).
29
30
31
32

1
2
3 However, it should be noted that due to ambident nature of the nucleophile **A** employed an
4 alternative reaction scenario is also possible (Scheme 2, bottom, cascade B). It can be initiated
5 through the Michael addition of **A** via C-3 nucleophilic position to the iminium-ion-activated
6 enal **1**. Subsequent cyclization via intramolecular Michael addition and re-oxidation should
7 afford undesired **4**.
8
9

10
11 Herein, we present our studies on the first application of 2-substituted-1,4-naphthoquinones **1**
12 as vinylogous pronucleophiles in asymmetric organocatalysis. Careful optimization of reaction
13 conditions enabled to control the site-selectivity of the cascade providing an efficient and
14 stereoselective access to carboannulated naphthalen-1(4*H*)-ones **3** (Scheme 2, bottom, cascade
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Scheme 2. 2-Substituted-1,4-naphthoquinones **1** in asymmetric organocatalysis and the objectives of our studies

Results and Discussion

1
2
3 Optimization studies were initiated using 2-benzyl-1,4-naphthoquinone **1a** and
4
5 cinnamaldehyde **2a** as model reagents (Table 1). Initial experiment performed in
6
7 dichloromethane in the presence of diphenylprolinol trimethylsilyl ether **5a**⁹ as aminocatalyst
8
9 and sodium acetate as basic co-catalyst confirmed the viability of our synthetic hypothesis (Table
10
11 1, entry 1). Disappointingly, the conversion to **3a** was low and the formation of the side-product
12
13 **4a** arising from the alternative reaction mechanism (Scheme 2, cascade B) was observed. To our
14
15 delight, both diastereoselectivity and enantioselectivity of the process were excellent. In order to
16
17 improve the conversion and suppress the formation of **4a**, the co-catalyst screening was
18
19 performed (Table 1, entries 1-5). Among compounds tested the use of amphiprotic additive (4-
20
21 (dimethylamino)benzoic acid, DMABA) provided the best conversion and limited the formation
22
23 of **3a** to the highest extent (Table 1, entry 5). In the course of the further studies the influence of
24
25 various aminocatalyst **5** on the reaction outcome was evaluated (Table 1, entries 5-8) indicating
26
27 that the alteration of **5** did not improve the results. Similarly, the change of solvent was not
28
29 beneficial for the developed cascade (Table 1, compare entries 5, 9-11). Therefore, the influence
30
31 of the relative ratio of reactants and temperature on the reaction was tested (Table 1, entries
32
33 12,13). The use of **2a** as limiting factor and performing the reaction at 5 °C for longer time
34
35 enabled to increase the conversion with the high chemo- and stereoselectivity of the process
36
37 being maintained (Table 1, entry 13). Notably, for the convenience of the project the catalyst
38
39 loading was increased to 30 mol% in order to achieve full conversion within shorter timeframe
40
41 and similar results were obtained (Table 1, entry 14).
42
43
44
45
46
47
48


49 **Table 1.** 2-Substituted-1,4-naphthoquinones **1** as vinylogous pronucleophiles in asymmetric
50 organocatalysis – optimization studies^a
51
52
53
54
55
56
57
58
59
60



	Catalyst (additive)	Solvent	Conv. ^b (yield)	3a:4a	dr ^c	er ^d
1	5a (NaOAc)	CH ₂ Cl ₂	41	3.3:1	>20:1	99:1
2	5a (Et ₃ N)	CH ₂ Cl ₂	18	>20:1	>20:1	n.d.
3	5a (Li ₂ CO ₃)	CH ₂ Cl ₂	39	3.3:1	>20:1	n.d.
4	5a (K ₂ CO ₃)	CH ₂ Cl ₂	<5	n.d.	n.d.	n.d.
5	5a (DMABA)	CH ₂ Cl ₂	50 (34)	11:1	>20:1	99:1
6	5b (DMABA)	CH ₂ Cl ₂	34	11:1	>20:1	n.d.
7	5c (DMABA)	CH ₂ Cl ₂	33	8:1	>20:1	n.d.
8	5d (DMABA)	CH ₂ Cl ₂	<5	n.d.	n.d.	n.d.
9	5a (DMABA)	toluene	13	>20:1	>20:1	n.d.
10	5a (DMABA)	CCl ₄	12	>20:1	>20:1	n.d.
11	5a (DMABA)	CHCl ₃	36	7:1	>20:1	n.d.
12 ^e	5a (DMABA)	CH ₂ Cl ₂	61	10:1	>20:1	n.d.
13 ^f	5a (DMABA)	CH ₂ Cl ₂	93 (64)	12:1	>20:1	99:1
14 ^g	5a (DMABA)	CH ₂ Cl ₂	97 (67)	12:1	>20:1	99:1

^a Reactions performed on a 0.1 mmol scale employing **1a** (1.0 equiv), **2a** (1.2 equiv), catalyst **5a** (20 mol%) with additive (20 mol%) in 0.4 mL of the solvent at room temperature (for detailed reaction conditions and screening results, see Supporting Information). ^b Conversion was determined by ¹H NMR of a crude reaction mixture. Isolated yield is given in parentheses. ^c Determined by ¹H NMR of a crude reaction mixture. ^d Determined by chiral stationary phase HPLC. ^e Reaction performed using **1a** (2 equiv) and **2a** (1 equiv). ^f Reaction performed using **1a** (2 equiv) and **2a** (1 equiv) at 5 °C for 6 days. ^g Reaction performed using **1a** (2 equiv) and **2a** (1 equiv) at 5 °C using catalyst **5a** (30 mol%) for 3 days.


Being successful in accomplishing optimization studies, the scope of developed cascade reactivity was studied (Scheme 3, Table 2). Initially, the performance of various 2-substituted-1,4-naphthoquinones **1** as vinylogous pronucleophiles in the developed cascade was tested (Scheme 3). To our delight, the reaction cascade involving Michael addition followed by the aldol condensation proved unbiased towards the position of groups on the aromatic substituent in the benzyl moiety of **1** (Scheme 3, compare **3b-d**). Furthermore, their electronic properties had no significant impact on the cascade outcome (Scheme 3, compare **3b,e,f**). Notably, in all of the cases the excellent enantio- and diastereoselectivity of the process was fully maintained. Furthermore, chemoselectivity of the cascade was high with the side-reaction initiated through the Michael addition from the C-3 position of the naphthoquinone ring being suppressed to high extent. It is worth to stress out that when 1,4-naphthoquinone bearing methyl substituent instead of benzyl group in the 2 position was employed no reaction was observed.



Scheme 3. 2-Substituted-1,4-naphthoquinones **1** as vinylogous pronucleophiles in asymmetric organocatalysis - 2-substituted-1,4-naphthoquinone **1** scope

Subsequently, various α,β -unsaturated aldehydes **2** were evaluated in the developed cascade (Table 2). It was found that the presence of both electron-withdrawing groups (Table 2, entries 2-8) as well as electron-donating groups (Table 2, entries 9-11) on the aromatic substituent in **2** did not affect the cascade providing the target products **3** in a highly enantio- and diastereoselective fashion. The reaction outcome did also not depend from the location of the substituent on the aromatic moiety in **2** (Table 2, entries 6-8 vs. 10,11). Notably, the use of aliphatic, linear enals resulted in sluggish conversion.

Table 2. 2-Substituted-1,4-naphthoquinones **1** as vinylogous pronucleophiles in asymmetric organocatalysis – α,β -unsaturated aldehyde **2** scope^a




	R	Yield [%]	dr ^b	er ^c
1	Ph (3a)	67	>20:1	99:1
2	4-CF ₃ C ₆ H ₄ (3g)	54	>20:1	99:1
3	4-NO ₂ C ₆ H ₄ (3h)	47	>20:1	99.5:0.5
4	2-NO ₂ C ₆ H ₄ (3i)	50	>20:1	99.5:0.5
5	4-BrC ₆ H ₄ (3j)	55	>20:1	99:1
6	4-ClC ₆ H ₄ (3k)	52	>20:1	99:1
7	3-ClC ₆ H ₄ (3l)	56	>20:1	99:1
8	2-ClC ₆ H ₄ (3m)	64	>20:1	99.5:0.5

9	4-MeC ₆ H ₄ (3n)	61	>20:1	98.5:1.5
10	4-(MeO)C ₆ H ₄ (3o)	47	>20:1	98.5:1.5
11	2-(MeO)C ₆ H ₄ (3p)	70	>20:1	>99.5:0.5
12	2,4-Cl ₂ C ₆ H ₃ (3q)	62	>20:1	99:1
13 ^d	Ph (3a)	70	>20:1	99:1

^a Reactions realized on a 0.1 mmol scale using **1** (2.0 equiv) and **2a** (1.0 equiv) in 0.4 mL of CH₂Cl₂ for 2-6 days. ^b Determined by ¹H NMR of a crude reaction mixture. ^c Determined by a chiral stationary phase HPLC. ^d The reaction performed on a 1 mmol scale.

Furthermore, disubstituted aromatic rings were well-tolerated as presented in the cascade leading to the formation of **3q** (Table 2, entry 12). It is worth to note that the developed cascade was also performed in a 10-fold larger scale (Table 2, entry 13) providing **3a** with comparable results to those obtained on a 0.1 mmol scale (Table 2, entry 1), thus increasing the attractiveness of our approach.


Absolute configuration of the product **3b** was unequivocally confirmed by the single crystal X-ray experiment (Scheme 4).¹⁰ The same absolute configuration was assigned by analogy to the remaining naphthalen-1(4*H*)-ones **3a,c-q**.



Scheme 4. 2-Substituted-1,4-naphthoquinones **1** as vinylogous pronucleophiles in asymmetric organocatalysis – absolute configuration assignment

Given the stereochemical assignments, a plausible reaction mechanism was proposed (Scheme 5). It is postulated that the reaction cascade is initiated by two parallel processes. Firstly, 2-substituted-1,4-naphthoquinone **1** is deprotonated to generate the corresponding dienolate **A**. Secondly, enal **2** is activated through the iminium ion **B** formation. Subsequently, the first C-C

1
2
3 bond-forming event takes place. Enantioselectivity of the Michael addition of **1** to **2** is controlled
4
5 by the bulky substituent present at the C-2 of the pyrrolidine moiety in **B**. Notably, the
6
7 diastereoselectivity of the addition is a consequence of dienolate **A** reacting in its *E,Z*-
8
9 configuration (Scheme 5, TS-1). Dienolate **A** adopts such a reactive configuration in order to
10
11 avoid disfavored interactions (between R^2 substituent and the sterically demanding substituent of
12
13 the iminium ion **B**) that are present in the alternative transition state (Scheme 5, TS-2)
14
15 proceeding through the *E,E*-configured dienolate **A**. The conjugate addition leads to the
16
17 formation of enamine **6** that undergoes intramolecular aldol reaction to give iminium ion **7**.
18
19 Subsequent dehydration and hydrolytic removal of the catalyst affords target product **3**.
20
21
22
23



Scheme 5. 2-Substituted-1,4-naphthoquinones **1** as vinylogous pronucleophiles in asymmetric organocatalysis – mechanistic considerations

Conclusions

In conclusion, we have demonstrated for the first time that 2-substituted-1,4-naphthoquinones **1** can serve as pronucleophiles thus providing new opportunities for organic synthesis. The reaction between **1** and α,β -unsaturated aldehydes **2** proceeded in a vinylogous fashion providing carboannulated naphthalen-1(4*H*)-ones **3** in a sequence of reaction involving Michael addition followed by the intramolecular aldol condensation. The proper choice of reaction conditions enabled the control of both the site- and stereo-selectivity of the cascade.

Experimental Section

General Information. Unless otherwise noted, analytical grade solvents and commercially available reagents were used without further purification. NMR spectra were acquired on a Bruker Ultra Shield 700 instrument, running at 700 MHz for ^1H and 176 MHz for ^{13}C , respectively. Chemical shifts (δ) are reported in ppm relative to residual solvent signals (CDCl_3 : 7.26 ppm for ^1H NMR, 77.16 ppm for ^{13}C NMR). Mass spectra were recorded on a spectrometer using electrospray ionization (ESI+) using TOF mass analyzer (referenced to the mass of the charged species). Optical rotations were measured on a Perkin-Elmer 241 polarimeter and $[\alpha]_D$ values are given in $\text{deg}\cdot\text{cm}\cdot\text{g}^{-1}\cdot\text{dm}^{-1}$; concentration c is listed in $\text{g}\cdot(100\text{ mL})^{-1}$. Melting points were determined in open capillaries and are uncorrected. Analytical thin layer chromatography (TLC) was performed using pre-coated aluminum-backed plates (Merck Kieselgel 60 F254) and visualized by ultraviolet irradiation. The enantiomeric ratio (*er*) of the products was determined by chiral stationary phase HPLC (Daicel Chiralpak IA, IC and ID column). For flash chromatography (FC) silica gel (Silica gel 60, 230-400 mesh, Fluka) was used. 2-Substituted-

1
2
3 1,4-naphthoquinones **1a-f**¹¹ and aldehydes **2g-q**¹² were synthesized from the corresponding
4
5 benzaldehydes according to literature procedures.
6
7

8
9 *Synthesis of 2- substituted-1,4-naphthoquinone I – general procedure.* AgNO₃ (1 mmol) and
10
11 (NH₄)₂S₂O₈ (20 mmol) were dissolved in water (40 mL) and a solution of 1,4-naphthoquinone
12
13 (10 mmol) and 2-phenylacetic acid (20 mmol) in a 1:1 mixture of acetonitrile/dichloromethane
14
15 (40 mL) was quickly added. The biphasic mixture was refluxed (bath temperature ca. 80 °C) for
16
17 2 hours, cooled to ambient temperature, and dichloromethane (40 mL) was added. The aqueous
18
19 layer was separated and extracted again with dichloromethane (40 mL). The combined organic
20
21 layers were dried (anhydrous sodium sulphate) and evaporated. Resulting brown oil was purified
22
23 by column chromatography (hexane:EtOAc 100:1). Pure products were obtained as yellow
24
25 solids.
26
27
28
29

30
31 *2-Benzyl-1,4-naphthoquinone 1a.* Following general procedure, pure product **1a** was isolated
32
33 by FC on silica (hexane:diethyl ether 100:1) in 71% yield as an yellow solid (mp = 85-86 °C). ¹H
34
35 NMR (700 MHz, CDCl₃) δ 8.12–8.10 (m, 1H), 8.06-8.03 (m, 1H), 7.73–7.72 (m, 2H), 7.35-7.33
36
37 (m, 2H), 7.27–7.25 (m, 3H), 6.61 (t, *J* = 1.6 Hz, 1H), 3.90 (d, *J* = 1.4 Hz, 2H). ¹³C NMR (176
38
39 MHz, CDCl₃) δ 185.3, 185.2, 151.0, 136.9, 135.8, 134.0, 133.9, 132.4, 132.2, 129.6 (2C), 129.0
40
41 (2C), 127.1, 126.8, 126.3, 35.9. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₇H₁₃O₂ 249.0910;
42
43 Found: 249.0913.
44
45
46

47
48 *2-(4-Chlorobenzyl)-1,4-naphthoquinone 1b.* Following general procedure, pure product **1b**
49
50 was isolated by FC on silica (hexane:diethyl ether 100:1) in 57% yield as an yellow solid (mp =
51
52 98-100 °C). ¹H NMR (700 MHz, CDCl₃) δ 8.10 (ddd, *J* = 4.6, 3.0, 0.5 Hz, 1H), 8.05 (ddd, *J* =
53
54 3.9, 3.0, 0.5 Hz, 1H), 7.75–7.71 (m, 2H), 7.32–7.28 (m, 2H), 7.21–7.17 (m, 2H), 6.62 (t, *J* = 1.5
55
56
57
58
59
60

1
2
3 Hz, 1H), 3.87 (d, $J = 1.4$ Hz, 2H). ^{13}C NMR (176 MHz, CDCl_3) δ 185.1, 185.0, 150.4, 136.0,
4
5 135.4, 134.0, 134.0, 133.1, 132.2, 132.2, 131.0 (2C), 129.1 (2C), 126.8, 126.3, 35.3. HRMS
6
7 (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{17}\text{H}_{12}\text{ClO}_2$ 283.0520; Found: 283.0526.
8
9

10
11 *2-(3-Chlorobenzyl)-1,4-naphthoquinone 1c*. Following general procedure, pure product **1c** was
12
13 isolated by FC on silica (hexane:diethyl ether 100:1) in 43% yield as a yellow solid (mp = 75-
14
15 77 °C). ^1H NMR (700 MHz, CDCl_3) δ 8.11 (ddd, $J = 4.8, 2.9, 0.5$ Hz, 1H), 8.06 (ddd, $J = 4.1,$
16
17 2.9, 0.5 Hz, 1H), 7.74 (ddd, $J = 5.0, 4.5, 3.6$ Hz, 2H), 7.29–7.21 (m, 3H), 7.14 (dt, $J = 7.2, 1.6$
18
19 Hz, 1H), 6.63 (t, $J = 1.5$ Hz, 1H), 3.87 (d, $J = 1.3$ Hz, 2H). ^{13}C NMR (176 MHz, CDCl_3) δ 185.1,
20
21 184.9, 150.1, 139.0, 136.0 (2C), 134.8, 134.0, 133.9, 132.2, 130.2, 129.6, 127.7, 127.4, 126.9,
22
23 126.3, 35.6. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{17}\text{H}_{12}\text{ClO}_2$ 283.0520; Found:
24
25 283.0522.
26
27
28
29

30
31 *2-(2-Chlorobenzyl)-1,4-naphthoquinone 1d*. Following general procedure, pure product **1d**
32
33 was isolated by FC on silica (hexane:diethyl ether 100:1) in 68% yield as a yellow solid (mp =
34
35 108–110 °C). ^1H NMR (700 MHz, CDCl_3) δ 8.16–8.12 (m, 1H), 8.07–8.03 (m, 1H), 7.75–7.73
36
37 (m, 2H), 7.42–7.41 (m, 1H), 7.28–7.23 (m, 3H), 6.44 (t, $J = 1.7$ Hz, 1H), 4.05 (d, $J = 1.7$ Hz, 2H).
38
39 ^{13}C NMR (176 MHz, CDCl_3) δ 185.1, 185.0, 149.3, 135.7, 134.7, 133.9 (2C), 132.3 (2C), 132.0,
40
41 130.1, 128.9, 127.4, 126.8 (2C), 126.3, 33.5. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for
42
43 $\text{C}_{17}\text{H}_{12}\text{ClO}_2$ 283.0520; Found: 283.0517.
44
45
46

47
48 *2-(p-Tolyl)-1,4-naphthoquinone 1e*. Following general procedure, pure product **1e** was isolated
49
50 by FC on silica (hexane:diethyl ether 100:1) in 69% yield as a yellow solid (mp = 90–93 °C). ^1H
51
52 NMR (700 MHz, CDCl_3) δ 8.15–8.11 (m, 1H), 8.09–8.04 (m, 1H), 7.76–7.72 (m, 2H), 7.20–7.17
53
54 (m, 2H), 6.91–6.88 (m, 2H), 6.62 (t, $J = 1.5$ Hz, 1H), 3.86 (d, $J = 1.5$ Hz, 2H), 3.82 (s, 3H). ^{13}C
55
56
57
58
59
60

1
2
3 NMR (176 MHz, CDCl₃) δ 185.0, 184.9, 150.1, 139.0 (2C), 136.0, 134.8 (2C), 134.0, 133.9,
4
5 132.2, 130.2, 129.6, 127.7, 127.4, 126.9, 126.3, 35.5. HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for
6
7 C₁₈H₁₅O₂ 263.1067; Found: 263.1062.
8
9

10
11 *2-(4-Methoxybenzyl)-1,4-naphthoquinone 1f*. Following general procedure, pure product **1f**
12
13 was isolated by FC on silica (hexane:diethyl ether 100:1) in 71% yield as an yellow solid (mp =
14
15 74-76 °C). ¹H NMR (700 MHz, CDCl₃) δ 8.10–8.09 (m, 1H), 8.04–8.03 (m, 1H), 7.72–7.71 (m,
16
17 2H), 7.17–7.15 (m, 2H), 6.87–6.86 (m, 2H), 6.60 (t, *J* = 1.5 Hz, 1H), 3.84 (d, *J* = 1.5 Hz, 2H),
18
19 3.79 (s, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 185.3, 185.2, 158.7, 151.4, 135.6, 133.9, 133.8,
20
21 132.3, 132.2, 130.6 (2C), 128.7, 126.8, 126.2, 114.4 (2C), 55.4, 35.1. HRMS (ESI-TOF) m/z: [M
22
23 + H]⁺ Calcd for C₁₈H₁₅O₃ 279.1016; Found: 279.1022.
24
25
26
27

28 *General Procedure for the Synthesis of Compounds 3a-q*. In an ordinary 4 mL glass vial,
29
30 equipped with a magnetic stirring bar and a screw cap, catalyst **5a** (0.3 equiv, 0.03 mmol, 9.8
31
32 mg) and *α,β*-unsaturated aldehyde **2** (1.0 equiv, 0.1 mmol) were dissolved in CH₂Cl₂ (0.2 mL).
33
34 Subsequently, the mixture was cooled to 5 °C and a solution of the corresponding 2-alkyl-1,4-
35
36 naphthoquinone **1** (2 equiv, 0.2 mmol) and 4-dimethylaminobenzoic acid (0.2 equiv, 0.02 mmol,
37
38 3.3 mg) in CH₂Cl₂ (0.2 mL) was added and stirring was continued for 2-6 days at 5 °C. Crude
39
40 product was purified by the flash chromatography on silica gel.
41
42
43
44

45 *(2R,3R)-5-Oxo-2,3-diphenyl-3,5-dihydro-2H-cyclopenta[a]naphthalene-1-carbaldehyde 3a*.
46
47 Following general procedure, pure product **3a** was isolated after 3 days by FC on silica
48
49 (hexane:diethyl ether 4:1) in 67% yield (24 mg, >20:1 dr, **3a:4a** 90:10) as an yellow solid (mp =
50
51 88-90 °C). ¹H NMR (700 MHz, CDCl₃) δ 10.64 (s, 1H), 8.35–8.31 (m, 1H), 8.29–8.22 (m, 1H),
52
53 7.78–7.68 (m, 2H), 7.35–7.28 (m, 5H), 7.27-7.25 (m, 1H), 7.17–7.09 (m, 4H), 6.40 (dd, *J* = 2.0,
54
55
56
57
58
59
60

0.8 Hz, 1H), 4.55 (d, $J = 2.7$ Hz, 1H), 4.18 (t, $J = 2.4$ Hz, 1H). ^{13}C NMR (176 MHz, CDCl_3) δ 189.3, 184.6, 166.7, 148.9, 142.1, 141.7, 141.2, 132.5, 131.9, 131.4, 130.2, 129.3 (2C), 129.2 (2C), 128.7, 128.0, 127.8 (2C), 127.7, 127.6, 127.5 (2C), 125.8, 60.5, 57.2. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{26}\text{H}_{19}\text{O}_2 + \text{H}^+$ 363.1380; Found: 363.1387. The *er* was determined by HPLC using a chiral Chiralpack IA [hexane:*i*-PrOH, 90:10] column; column temperature 30 °C; flow rate 1.0 mL/min; $t_{\text{major}} = 10.7$ min, $t_{\text{minor}} = 13.4$ min (99:1 *er*); $[\alpha]_{\text{D}}^{20} = -254.3$ ($c = 1.0$, CHCl_3).

(2*R*,3*R*)-3-(4-Chlorophenyl)-5-oxo-2-phenyl-3,5-dihydro-2*H*-cyclopenta[*a*]naphthalene-1-carbaldehyde **3b**. Following general procedure, pure product **3b** was isolated after 2 days by FC on silica (hexane:diethyl ether 4:1) in 72% yield (29 mg, >20:1 dr, **3b:4b** 91:9) as a green solid (mp = 130-132 °C). ^1H NMR (700 MHz, CDCl_3) δ 10.63 (s, 1H), 8.36–8.32 (m, 1H), 8.27–8.22 (m, 1H), 7.77–7.69 (m, 2H), 7.34–7.30 (m, 4H), 7.28–7.26 (m, 1H), 7.15–7.12 (m, 2H), 7.07–7.04 (m, 2H), 6.37 (d, $J = 1.5$ Hz, 1H), 4.48 (d, $J = 2.8$ Hz, 1H), 4.15 (t, $J = 2.4$ Hz, 1H). ^{13}C NMR (176 MHz, CDCl_3) δ 189.2, 184.4, 166.0, 148.6, 142.0, 141.4, 139.6, 133.7, 132.6, 131.8, 131.5, 130.1, 129.5, 129.3, 129.2 (2C), 128.7 (2C), 128.1 (2C), 127.7, 127.4 (2C), 125.8, 60.5, 56.6. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{26}\text{H}_{18}\text{ClO}_2$ 397.0990; Found: 397.0991. The *er* was determined by HPLC using a chiral Chiralpack IC [hexane:*i*-PrOH, 80:20] column; column temperature 30 °C; flow rate 1.0 mL/min; $t_{\text{major}} = 17.9$ min, $t_{\text{minor}} = 22.1$ min (98.5:1.5 *er*); $[\alpha]_{\text{D}}^{20} = -256.3$ ($c = 1.0$, CHCl_3).

(2*R*,3*R*)-3-(3-Chlorophenyl)-5-oxo-2-phenyl-3,5-dihydro-2*H*-cyclopenta[*a*]naphthalene-1-carbaldehyde **3c**. Following general procedure, pure product **3c** was isolated after 2 days by FC on silica (hexane:diethyl ether 4:1) in 52% yield (21 mg, 18:1 dr, **3c:4c** 88:12) as an yellow solid (mp = 118-120 °C). ^1H NMR (700 MHz, CDCl_3) δ 10.63 (s, 1H), 8.36–8.32 (m, 1H), 8.26–8.23

(m, 1H), 7.76–7.71 (m, 2H), 7.34–7.30 (m, 2H), 7.30–7.27 (m, 3H), 7.16–7.12 (m, 2H), 7.12–7.09 (m, 1H), 7.02–6.98 (m, 1H), 6.39 (dd, $J = 2.0, 0.6$ Hz, 1H), 4.52 (d, $J = 2.7$ Hz, 1H), 4.16–4.10 (m, 1H). ^{13}C NMR (176 MHz, CDCl_3) δ 189.1, 184.4, 165.8, 148.6, 143.2, 141.9, 141.4, 135.2, 132.6, 131.8, 131.6, 130.6, 130.1, 129.3 (2C), 128.7, 128.1, 128.0, 127.9, 127.7, 127.4 (2C), 126.1, 126.0, 60.3, 56.7. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{26}\text{H}_{18}\text{ClO}_2$ 397.0990; found: 397.0999. The *er* was determined by HPLC using a chiral Chiralpack IC [hexane:*i*-PrOH, 80:20] column; column temperature 30 °C; flow rate 1.0 mL/min; $t_{\text{major}} = 16.0$ min, $t_{\text{minor}} = 18.6$ min (99:1 *er*); $[\alpha]_{\text{D}}^{20} = -258.8$ ($c = 1.0$, CHCl_3).

(2*R*,3*S*)-3-(2-Chlorophenyl)-5-oxo-2-phenyl-3,5-dihydro-2*H*-cyclopenta[*a*]naphthalene-1-carbaldehyde **3d**. Following general procedure, pure product **3d** was isolated after 5 days by FC on silica (hexane:diethyl ether 4:1) in 65% yield (26 mg, >20:1 dr, **3d:4d** 98:2) as a green amorphous solid. ^1H NMR (700 MHz, CDCl_3) δ 10.62 (s, 1H), 8.37–8.33 (m, 1H), 8.27–8.23 (m, 1H), 7.75–7.70 (m, 2H), 7.42 (dd, $J = 7.9, 1.5$ Hz, 1H), 7.31 (dd, $J = 10.2, 4.7$ Hz, 2H), 7.27–7.23 (m, 3H), 7.21 (td, $J = 7.5, 1.5$ Hz, 1H), 7.18 (d, $J = 7.2$ Hz, 2H), 7.05 (dd, $J = 7.5, 1.5$ Hz, 1H), 6.41 (bs, 1H), 4.66 (bs, 1H), 4.60 (bs, 1H). ^{13}C NMR (176 MHz, CDCl_3) δ 189.2, 184.5, 165.8, 149.0, 141.8, 141.6, 134.2, 132.5, 131.9, 131.4, 130.4, 130.2, 129.1 (2C), 129.0 (3C), 128.7, 128.0, 127.6 (4C), 125.4, 59.1, 58.9. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{26}\text{H}_{18}\text{ClO}_2$ 397.0990; Found: 397.0983. The *er* was determined by HPLC using a chiral Chiralpack IC [hexane:*i*-PrOH, 80:20] column; column temperature 30 °C; flow rate 1.0 mL/min; $t_{\text{major}} = 14.4$ min, $t_{\text{minor}} = 15.8$ min (99:1 *er*); $[\alpha]_{\text{D}}^{20} = -181.1$ ($c = 1.0$, CHCl_3).

(2*R*,3*R*)-5-Oxo-2-phenyl-3-(*p*-tolyl)-3,5-dihydro-2*H*-cyclopenta[*a*]naphthalene-1-carbaldehyde **3e**. Following general procedure, pure product **3e** was isolated after 6 days by FC on silica (hexane:diethyl ether 4:1) in 62% yield (23 mg, >20:1 dr, **3e:4e** 88:12) as an yellow

1
2
3 amorphous solid. ^1H NMR (700 MHz, CDCl_3) δ 10.63 (s, 1H), 8.33 (ddd, $J = 8.6, 4.1, 3.3$ Hz,
4 1H), 8.26–8.22 (m, 1H), 7.76–7.67 (m, 2H), 7.32–7.29 (m, 2H), 7.28–7.24 (m, 1H), 7.16–7.13
5 (m, 4H), 7.02–6.99 (m, 2H), 6.39 (dd, $J = 2.0, 0.7$ Hz, 1H), 4.53 (d, $J = 2.7$ Hz, 1H), 4.14 (t, $J =$
6 2.4 Hz, 1H), 2.34 (s, 3H). ^{13}C NMR (176 MHz, CDCl_3) δ 189.4, 184.6, 166.9, 149.0, 142.0,
7 141.8, 138.1, 137.4, 132.5, 131.9, 131.4, 130.2, 130.0 (2C), 129.2 (2C), 128.7, 128.0, 127.7 (2C),
8 127.5, 127.4 (2C), 125.7, 60.5, 56.9, 21.2. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{27}\text{H}_{21}\text{O}_2$
9 377.1537; Found: 377.1544. The *er* was determined by HPLC using a chiral Chiralpack IC
10 [hexane:*i*-PrOH, 80:20] column; column temperature 30 °C; flow rate 1.0 mL/min; $t_{\text{major}} = 15.5$
11 min, $t_{\text{minor}} = 18.0$ min (99:1 *er*); $[\alpha]_{\text{D}}^{20} = -214.2$ ($c = 1.0, \text{CHCl}_3$).
12
13
14
15
16
17
18
19
20
21
22
23

24
25 (2*R*,3*S*)-3-(4-Methoxyphenyl)-5-oxo-2-phenyl-3,5-dihydro-2*H*-cyclopenta[*a*]naphthalene-1-
26 *carbaldehyde* **3f**. Following general procedure, pure product **3f** was isolated after 5 days by FC
27 on silica (hexane:diethyl ether 4:1) in 55% yield (22 mg, >20:1 *dr*, **3f**:**4f** 87:13) as an yellow
28 amorphous solid. ^1H NMR (700 MHz, CDCl_3) δ 10.62 (s, 1H), 8.35–8.31 (m, 1H), 8.26–8.23 (m,
29 1H), 7.74–7.69 (m, 2H), 7.33–7.28 (m, 2H), 7.28–7.23 (m, 1H), 7.16–7.12 (m, 2H), 7.05–7.01
30 (m, 2H), 6.88–6.83 (m, 2H), 6.38 (dd, $J = 2.0, 0.6$ Hz, 1H), 4.50 (d, $J = 2.8$ Hz, 1H), 4.12 (t, $J =$
31 2.4 Hz, 1H), 3.80 (s, 3H). ^{13}C NMR (176 MHz, CDCl_3) δ 189.4, 184.6, 167.0, 159.2, 148.9,
32 142.0, 141.8, 133.1, 132.5, 131.9, 131.4, 130.2, 129.2 (2C), 128.9 (2C), 128.7, 128.0, 127.5,
33 127.4 (2C), 125.6, 114.7 (2C), 60.7, 56.6, 55.5. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for
34 $\text{C}_{27}\text{H}_{21}\text{O}_3$ 393.1486; Found: 393.1490. The *er* was determined by HPLC using a chiral
35 Chiralpack IC [hexane:*i*-PrOH, 80:20] column; column temperature 30 °C; flow rate 1.0
36 mL/min; $t_{\text{major}} = 25.4$ min, $t_{\text{minor}} = 28.1$ min (99.5:0.5 *er*); $[\alpha]_{\text{D}}^{20} = -256.3$ ($c = 1.0, \text{CHCl}_3$).
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52
53 (2*R*,3*R*)-5-Oxo-3-phenyl-2-(4-(trifluoromethyl)phenyl)-3,5-dihydro-2*H*-
54 *cyclopenta*[*a*]naphthalene-1-*carbaldehyde* **3g**. Following general procedure, pure product **3g**
55
56
57
58
59
60

1
2
3 was isolated after 3 days by FC on silica (hexane:diethyl ether 4:1) in 54% yield (23 mg, >20:1
4 dr, **3g:4g** 93:7) as an yellow amorphous solid. ¹H NMR (700 MHz, CDCl₃) δ 10.71 (s, 1H),
5
6 8.36–8.32 (m, 1H), 8.23–8.18 (m, 1H), 7.78–7.71 (m, 2H), 7.57 (d, *J* = 8.1 Hz, 2H), 7.36–7.32
7
8 (m, 2H), 7.31 (m, 1H), 7.27–7.25 (d, *J* = 8.1 Hz, 2H), 7.12–7.08 (m, 2H), 6.39 (dd, *J* = 2.1, 0.8
9
10 Hz, 1H), 4.58 (d, *J* = 3.0 Hz, 1H), 4.13 (dd, *J* = 3.0, 2.1 Hz, 1H). ¹³C NMR (176 MHz, CDCl₃)
11
12 188.7, 184.4, 166.0, 147.7, 145.9, 143.6, 140.6, 132.6, 131.9, 131.7, 130.0, 129.8 (q, *J*_{C-F} = 32.6
13
14 Hz), 129.5 (2C), 128.7, 128.2, 128.0, 127.8 (2C), 127.7 (2C), 126.2 (q, *J*_{C-F} = 3.7 Hz, 2C), 126.0,
15
16 124.2 (q, *J*_{C-F} = 273.0 Hz), 59.9, 57.0. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₇H₁₈F₃O₂
17
18 431.1253; Found: 431.1255. The *er* was determined by HPLC using a chiral Chiralpack IC
19
20 [hexane:*i*-PrOH, 90:10] column; column temperature 30 °C; flow rate 1.0 mL/min; *t*_{major} = 19.3
21
22 min, *t*_{minor} = 21.0 min (99:1 *er*); [α]_D²⁰ = -211.6 (*c* = 1.0, CHCl₃).

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(2R,3R)-2-(4-Nitrophenyl)-5-oxo-3-phenyl-3,5-dihydro-2H-cyclopenta[*a*]naphthalene-1-
carbaldehyde **3h**. Following general procedure, pure product **3h** was isolated after 4 days by FC
on silica (hexane:diethyl ether 4:1) in 47% yield (19 mg, >20:1 dr, **3h:4h** 88:12) as an yellow
solid (mp = 123-125 °C). ¹H NMR (700 MHz, CDCl₃) δ 10.75 (s, 1H), 8.36–8.31 (m, 1H), 8.19
(dd, *J* = 7.4, 1.6 Hz, 1H), 8.17 (d, *J* = 8.8 Hz, 2H), 7.77–7.74 (m, 2H), 7.38–7.32 (m, 3H), 7.31
(d, *J* = 8.8 Hz, 2H), 7.13–7.08 (m, 2H), 6.38 (dd, *J* = 2.1, 0.7 Hz, 1H), 4.60 (d, *J* = 3.3 Hz, 1H),
4.12 (dd, *J* = 3.3, 2.1 Hz, 1H). ¹³C NMR (176 MHz, CDCl₃) δ 188.5, 184.3, 165.5, 149.4, 148.9,
147.3, 146.8, 143.8, 140.1, 132.7, 131.9 (4C), 129.8, 129.5, 129.2, 128.7, 128.3, 128.2, 127.9,
126.1, 124.5, 124.4, 59.7, 56.9. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₆H₁₈NO₄
408.1230; Found: 408.1237. The *er* was determined by HPLC using a chiral Chiralpack IC
[hexane:*i*-PrOH, 80:20] column; column temperature 30 °C; flow rate 1.0 mL/min; *t*_{major} = 18.0
min, *t*_{minor} = 20.5 min (>99.5:0.5 *er*); [α]_D²⁰ = -383.8 (*c* = 1.0, CHCl₃).

1
2
3 (2*R*,3*R*)-2-(2-Nitrophenyl)-5-oxo-3-phenyl-3,5-dihydro-2*H*-cyclopenta[*a*]naphthalene-1-
4
5
6 *carbaldehyde* **3i**. Following general procedure, pure product **3i** was isolated after 3 days by FC
7
8 on silica (hexane:diethyl ether 4:1) in 50% yield (20 mg, >20:1 dr, **3i:4i** 82:18) as an yellow
9
10 amorphous solid. ¹H NMR (700 MHz, CDCl₃) δ 10.68 (s, 1H), 8.37–8.30 (m, 1H), 8.22–8.15 (m,
11
12 1H), 7.85 (dd, *J* = 8.3, 1.4 Hz, 1H), 7.78–7.71 (m, 2H), 7.51 (td, *J* = 7.4, 1.4 Hz, 1H), 7.40 (ddd,
13
14 *J* = 8.3, 7.4, 1.4 Hz, 1H), 7.36–7.30 (m, 3H), 7.22–7.18 (m, 1H), 7.16–7.11 (m, 2H), 6.38 (d, *J* =
15
16 1.6 Hz, 1H), 5.24 (bs, 1H), 4.27 (bs, 1H). ¹³C NMR (176 MHz, CDCl₃) δ 188.4, 184.3, 166.0,
17
18 165.5, 149.5, 147.1, 143.3, 140.2, 134.1, 133.3, 132.6, 131.8, 131.7, 129.9, 129.3 (2C), 128.7,
19
20 128.3, 128.1, 128.0, 127.9 (2C), 126.1, 125.0, 61.1, 56.7. HRMS (ESI-TOF) *m/z*: [M + H]⁺
21
22 Calcd for C₂₆H₁₈NO₄ 408.1230; Found: 408.1238. The *er* was determined by HPLC using a
23
24 chiral Chiralpack IC [hexane:*i*-PrOH, 90:10] column; column temperature 30 °C; flow rate 1.0
25
26 mL/min; *t*_{major} = 24.7 min, *t*_{minor} = 28.4 min (>99.5:0.5 *er*); [α]_D²⁰ = -157.6 (*c* = 1.0, CHCl₃).
27
28
29
30

31 (2*R*,3*R*)-2-(4-Bromophenyl)-5-oxo-3-phenyl-3,5-dihydro-2*H*-cyclopenta[*a*]naphthalene-1-
32
33
34 *carbaldehyde* **3j**. Following general procedure, pure product **3j** was isolated after 2 days by FC
35
36 on silica (hexane:diethyl ether 4:1) in 55% yield (24 mg, >20:1 dr, **3j:4j** 92:2) as an yellow solid
37
38 (mp = 130-132 °C). ¹H NMR (700 MHz, CDCl₃) δ 10.67 (s, 1H), 8.33 (m, 1H), 8.21 (m, 1H),
39
40 7.76–7.71 (m, 2H), 7.46–7.40 (m, 2H), 7.35–7.32 (m, 2H), 7.32–7.28 (m, 1H), 7.10 (m, 2H),
41
42 7.05–6.99 (m, 2H), 6.38 (dd, *J* = 2.0, 0.6 Hz, 1H), 4.49 (d, *J* = 2.9 Hz, 1H), 4.11–4.10 (m, 1H).
43
44 ¹³C NMR (176 MHz, CDCl₃) δ 188.9, 184.4, 166.2, 148.0, 143.0, 140.9, 140.7, 132.6, 132.3
45
46 (2C), 131.9, 131.6, 130.0, 129.4 (2C), 129.11 (2C), 128.7, 128.1, 127.9, 127.8 (2C), 125.9,
47
48 121.4, 59.7, 57.1. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₆H₁₈BrO₂ 441.0485; Found:
49
50 441.0477. The *er* was determined by HPLC using a chiral Chiralpack IC [hexane:*i*-PrOH, 80:20]
51
52
53
54
55
56
57
58
59
60

column; column temperature 30 °C; flow rate 1.0 mL/min; $t_{\text{major}} = 18.1$ min, $t_{\text{minor}} = 22.8$ min (99:1 *er*); $[\alpha]_{\text{D}}^{20} = -285.9$ ($c = 1.0$, CHCl_3).

(2*R*,3*R*)-2-(4-Chlorophenyl)-5-oxo-3-phenyl-3,5-dihydro-2*H*-cyclopenta[*a*]naphthalene-1-carbaldehyde **3k**. Following general procedure, pure product **3k** was isolated after 3 days by FC on silica (hexane:diethyl ether 4:1) in 52% yield (21 mg, >20:1 dr, **3k**:**4k** 93:7) as an yellow solid (mp = 118-120 °C). ^1H NMR (700 MHz, CDCl_3) δ 10.67 (s, 1H), 8.34–8.32 (m, 1H), 8.22–8.20 (m, 1H), 7.76–7.71 (m, 2H), 7.37–7.32 (m, 2H), 7.32–7.27 (m, 3H), 7.09 (m, 4H), 6.38 (dd, $J = 2.0, 0.6$ Hz, 1H), 4.50 (d, $J = 2.9$ Hz, 1H), 4.12–4.10 (m, 1H). ^{13}C NMR (176 MHz, CDCl_3) δ 189.7, 184.4, 166.2, 148.1, 142.7, 140.7, 140.3, 133.4, 132.6, 131.9, 131.6, 130.1, 129.4 (2C), 129.3 (2C), 128.8 (2C), 128.7, 128.1, 127.9, 127.8 (2C), 125.9, 59.6, 57.1. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{26}\text{H}_{18}\text{ClO}_2$ 397.0990; Found: 397.0988. The *er* was determined by HPLC using a chiral Chiralpack IC [hexane:*i*-PrOH, 80:20] column; column temperature 30 °C; flow rate 1.0 mL/min; $t_{\text{major}} = 17.0$ min, $t_{\text{minor}} = 21.3$ min (99:1 *er*); $[\alpha]_{\text{D}}^{20} = -336.8$ ($c = 1.0$, CHCl_3).

(2*R*,3*R*)-2-(3-Chlorophenyl)-5-oxo-3-phenyl-3,5-dihydro-2*H*-cyclopenta[*a*]naphthalene-1-carbaldehyde **3l**. Following general procedure, pure product **3l** was isolated after 2 days by FC on silica (hexane:diethyl ether 4:1) in 56% yield (22 mg, >20:1 dr, **3l**:**4l** 88:12) as a green amorphous solid. ^1H NMR (700 MHz, CDCl_3) δ 10.69 (s, 1H), 8.35–8.33 (m, 1H), 8.23–8.21 (m, 1H), 7.76–7.71 (m, 2H), 7.36–7.33 (m, 2H), 7.32–7.28 (m, 1H), 7.25–7.24 (m, 2H), 7.13–7.10 (m, 3H), 7.06–7.02 (m, 1H), 6.38 (dd, $J = 2.0, 0.7$ Hz, 1H), 4.50 (d, $J = 2.9$ Hz, 1H), 4.15–4.13 (m, 1H). ^{13}C NMR (176 MHz, CDCl_3) δ 188.9, 184.4, 166.1, 147.9, 143.9, 142.8, 140.8, 135.0, 132.6, 131.9, 131.6, 130.4, 130.0, 129.4 (2C), 128.7, 128.1, 127.9, 127.8 (2C), 127.7, 127.3, 126.0, 125.8, 59.8, 56.9. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{26}\text{H}_{18}\text{ClO}_2$ 397.0990;

1
2
3 Found: 397.0995. The *er* was determined by HPLC using a chiral Chiralpack IA [hexane:*i*-
4 PrOH, 90:10] column; column temperature 30 °C; flow rate 1.0 mL/min; $t_{\text{major}} = 11.2$ min, t_{minor}
5 = 13.7 min (99:1 *er*); $[\alpha]_{\text{D}}^{20} = -360.3$ ($c = 1.0$, CHCl_3).
6
7

8
9
10
11 *(2R,3R)*-2-(2-Chlorophenyl)-5-oxo-3-phenyl-3,5-dihydro-2H-cyclopenta[*a*]naphthalene-1-
12 *carbaldehyde* **3m**. Following general procedure, pure product **3m** was isolated after 2 days by
13 FC on silica (hexane:diethyl ether 4:1) in 64% yield (25 mg, >20:1 dr, **3m:4m** 91:9) as an yellow
14 solid (mp = 98-100 °C). ^1H NMR (700 MHz, CHCl_3) δ 10.68 (s, 1H), 8.35–8.31 (m, 1H), 8.25
15 (m, 1H), 7.78–7.68 (m, 2H), 7.38 (m, 1H), 7.35–7.31 (m, 2H), 7.31–7.27 (m, 1H), 7.27–7.17 (m,
16 2H), 7.17–7.13 (m, 2H), 7.06–7.03 (m, 1H), 6.37 (d, $J = 2.1$ Hz, 1H), 5.09 (bs, 1H), 4.19 (bs,
17 1H). ^{13}C NMR (176 MHz, CHCl_3) δ 188.8, 184.5, 166.4, 148.4, 142.6, 140.8, 133.8, 132.5,
18 131.8, 131.4 (2C), 130.4, 130.1, 129.2 (2C), 128.7 (2C), 128.6, 128.0, 127.9 (2C), 127.7, 127.5,
19 125.7, 56.4, 56.1. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{26}\text{H}_{18}\text{ClO}_2$ 397.0990; Found:
20 397.0993. The *er* was determined by HPLC using a chiral Chiralpack IC [hexane:*i*-PrOH, 80:20]
21 column; column temperature 30 °C; flow rate 1.0 mL/min; $t_{\text{major}} = 16.3$ min, $t_{\text{minor}} = 18.0$ min
22 (99.5:0.5 *er*); $[\alpha]_{\text{D}}^{20} = -121.9$ ($c = 1.0$, CHCl_3).
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39
40 *(2R,3R)*-5-Oxo-3-phenyl-2-(*p*-tolyl)-3,5-dihydro-2H-cyclopenta[*a*]naphthalene-1-
41 *carbaldehyde* **3n**. Following general procedure, pure product **3n** was isolated after 3 days by FC
42 on silica (hexane:diethyl ether 4:1) in 61% yield (23 mg, >20:1 dr, **3n:4n** 98:2) as a brown
43 amorphous solid. ^1H NMR (700 MHz, CDCl_3) δ 10.61 (s, 1H), 8.35–8.32 (m, 1H), 8.26–8.24 (m,
44 1H), 7.75–7.69 (m, 2H), 7.35–7.31 (m, 2H), 7.30–7.27 (m, 1H), 7.14–7.10 (m, 4H), 7.04 (d, $J =$
45 8.1 Hz, 2H), 6.39 (dd, $J = 2.0, 0.6$ Hz, 1H), 4.52 (d, $J = 2.6$ Hz, 1H), 4.16-4.15 (m, 1H), 2.33 (s,
46 3H). ^{13}C NMR (176 MHz, CDCl_3) δ 189.5, 184.6, 166.8, 149.1, 141.8, 141.2, 138.7, 137.3,
47 132.3, 131.9, 131.4, 130.3, 129.9 (2C), 129.3 (2C), 128.7, 128.0, 127.8 (2C), 127.7, 127.3 (2C),
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 125.7, 60.2, 57.3, 21.2. HRMS (ESI-TOF) m/z : $[M + H]^+$ Calcd for $C_{27}H_{21}O_2$ 377.1537; Found:
4 377.1530. The *er* was determined by HPLC using a chiral Chiralpack IC [hexane:*i*-PrOH, 80:20]
5
6 column; column temperature 30 °C; flow rate 1.0 mL/min; $t_{major} = 15.7$ min, $t_{minor} = 17.7$ min
7
8 (98.5:1.5 *er*); $[\alpha]_D^{20} = -199.9$ ($c = 1.0$, $CHCl_3$).
9

10
11
12
13 (2*R*,3*R*)-2-(4-Methoxyphenyl)-5-oxo-3-phenyl-3,5-dihydro-2*H*-cyclopenta[*a*]naphthalene-1-
14
15 *carbaldehyde* **3o**. Following general procedure, pure product **3o** was isolated after 2 days by FC
16 on silica (hexane:diethyl ether 4:1) in 47% yield (18 mg, >20:1 *dr*, **3o**:**4o** 93:7) as an yellow solid
17 (mp = 100-102 °C). 1H NMR (700 MHz, $CDCl_3$) δ 10.60 (s, 1H), 8.35–8.32 (m, 1H), 8.27–8.24
18 (m, 1H), 7.75–7.69 (m, 2H), 7.34–7.31 (m, 2H), 7.30–7.27 (m, 1H), 7.13–7.09 (m, 2H), 7.09–
19 7.05 (m, 2H), 6.87–6.82 (m, 2H), 6.39 (dd, $J = 2.0, 0.6$ Hz, 1H), 4.50 (d, $J = 2.7$ Hz, 1H), 4.15 (t,
20 $J = 2.4$ Hz, 1H), 3.79 (s, 3H). ^{13}C NMR (176 MHz, $CDCl_3$) δ 189.5, 184.6, 166.7, 159.1, 149.1,
21 141.6, 141.2, 133.7, 132.5, 131.9, 131.4, 130.3, 129.3 (2C), 128.7, 128.5 (2C), 128.0, 127.8 (2C),
22 127.7, 125.7, 114.6 (2C), 59.9, 57.4, 55.4. HRMS (ESI-TOF) m/z : $[M + H]^+$ Calcd for $C_{27}H_{21}O_3$
23 393.1486; Found: 393.1488. The *er* was determined by HPLC using a chiral Chiralpack IA
24 [hexane:*i*-PrOH, 90:10] column; column temperature 30 °C; flow rate 1.0 mL/min; $t_{major} = 14.3$
25 min, $t_{minor} = 21.5$ min (98.5:1.5 *er*); $[\alpha]_D^{20} = -193.7$ ($c = 1.0$, $CHCl_3$).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41
42 (2*R*,3*R*)-2-(2-Methoxyphenyl)-5-oxo-3-phenyl-3,5-dihydro-2*H*-cyclopenta[*a*]naphthalene-1-
43
44 *carbaldehyde* **3p**. Following general procedure, pure product **3p** was isolated after 4 days by FC
45 on silica (hexane:diethyl ether 4:1) in 70% yield (27 mg, >20:1 *dr*, **3p**:**4p** 89:11) as an yellow
46 solid (mp = 158-160 °C). 1H NMR (700 MHz, $CDCl_3$) δ 10.59 (s, 1H), 8.34–8.32 (m, 1H), 8.28–
47 8.26 (m, 1H), 7.74–7.68 (m, 2H), 7.33–7.30 (m, 2H), 7.28–7.26 (m, 1H), 7.26–7.23 (m, 1H),
48 7.15–7.13 (m, 2H), 7.00–6.98 (m, 1H), 6.90–6.87 (m, 2H), 6.36 (dd, $J = 2.0, 0.8$ Hz, 1H), 4.82
49 (d, $J = 2.8$ Hz, 1H), 4.22–4.18 (m, 1H), 3.66 (s, 3H). ^{13}C NMR (176 MHz, $CDCl_3$) δ 189.5,
50
51
52
53
54
55
56
57
58
59
60

1
2
3 184.8, 167.2, 157.1, 150.0, 141.6, 141.2, 132.4, 131.8, 131.1, 130.4, 129.3, 129.1, 129.0 (2C),
4
5 128.8, 128.6, 128.0 (2C), 127.9, 127.4, 125.1, 121.1, 111.4, 56.2, 55.7, 55.5. HRMS (ESI-TOF)
6
7 m/z: [M + H]⁺ Calcd for C₂₇H₂₁O₃ 393.1486; Found: 393.1481. The *er* was determined by HPLC
8
9 using a chiral Chiralpack ID [hexane:*i*-PrOH, 90:10] column; column temperature 30 °C; flow
10
11 rate 1.0 mL/min; *t*_{major} = 24.1 min, *t*_{minor} = 25.3 min (>99.5:0.5 *er*); [α]_D²⁰ = -199.9 (*c* = 1.0,
12
13 CHCl₃).

14
15
16
17
18 (2*S*,3*R*)-2-(2,4-Dichlorophenyl)-5-oxo-3-phenyl-3,5-dihydro-2*H*-cyclopenta[*a*]naphthalene-1-
19
20 *carbaldehyde* **3q**. Following general procedure, pure product **3q** was isolated after 3 days by FC
21
22 on silica (hexane:diethyl ether 4:1) in 62% yield (27 mg, >20:1 *dr*, **3q**:**4q** 99:1) as an yellow
23
24 amorphous solid. ¹H NMR (700 MHz, CDCl₃) δ 10.71 (s, 1H), 8.42–8.30 (m, 1H), 8.26–8.15 (m,
25
26 1H), 7.76–7.72 (m, 2H), 7.40 (m,1H), 7.35–7.28 (m, 3H), 7.18 (dd, *J* = 8.3, 2.2 Hz, 1H), 7.15–
27
28 7.12 (m, 2H), 6.98 (d, *J* = 8.3 Hz, 1H), 6.40–6.33 (m, 1H), 5.00 (bs, 1H), 4.14 (bs, 1H). ¹³C
29
30 NMR (176 MHz, CDCl₃) δ 188.5, 184.4, 165.9, 159.5, 147.9, 143.0, 140.5, 133.8, 132.6, 131.8,
31
32 131.6, 130.2, 130.0, 129.5, 129.3 (2C), 128.6, 128.1, 127.9 (2C), 127.9, 127.8, 127.0, 125.9,
33
34 62.0, 54.1. HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₂₆H₁₇Cl₂O₂ 431.0600; Found: 431.0609.
35
36 The *er* was determined by HPLC using a chiral Chiralpack IC [hexane:*i*-PrOH, 80:20] column;
37
38 column temperature 30 °C; flow rate 1.0 mL/min; *t*_{major} = 15.1 min, *t*_{minor} = 17.7 min (99:1 *er*);
39
40 [α]_D²⁰ = -147.7 (*c* = 1.0, CHCl₃).

41
42
43
44
45
46 **Supporting Information.** Full account of screening results, X-ray structure, copies of ¹H and
47
48 ¹³C NMR spectra, HPLC traces (PDF).
49

50 51 52 **AUTHOR INFORMATION**

53 54 55 **Corresponding Author**

1
2
3 e-mail: lukasz.albrecht@p.lodz.pl, www.a-teamlab.p.lodz.pl
4
5

6 **Author Contributions**

7
8 All authors have given approval to the final version of the manuscript. ‡ These authors
9 contributed equally.
10
11
12

13 **Funding Sources**

14
15
16
17 National Science Centre, Poland, Sonata Bis programme (grant number: 2015/18/E/ST5/00309)
18
19

20 **Notes**

21
22
23 The authors declare no competing financial interest.
24
25

26 **ACKNOWLEDGMENT**

27
28 This project was realized within the Sonata Bis programme (grant number:
29 2015/18/E/ST5/00309) from the National Science Centre, Poland. Thanks are expressed to Dr.
30
31 Jakub Wojciechowski (Faculty of Chemistry, Lodz University of Technology) for performing X-
32
33 ray analysis.
34
35
36
37

38 **REFERENCES**

39
40
41 (1) For selected reviews, see: (a) Nicolaou, K. C.; Snyder, S. A.; Montagnon, T.;
42 Vassilikogiannakis, G. *Angew. Chem., Int. Ed.* **2002**, *41*, 1668. (b) Moyano, A.; Rios, R. *Chem.*
43
44 *Rev.* **2011**, *111*, 4703. (c) Gouedranche, S.; Raimondi, W.; Bugaut, X.; Constantieux, T.;
45
46 Bonne, D.; Rodriguez, J. *Synthesis* **2013**, *45*, 1909.
47
48
49

50
51 (2) For selected reviews on organocatalytic multicyclic and domino synthetic strategies, see:
52
53 (a) Chauhan, P.; Mahajan, S.; Enders, D. *Acc. Chem. Res.* **2017**, *50*, 2809. (b) Wende, R. C.;
54
55 Schreiner, P. R. *Green Chem.* **2012**, *14*, 1821. (c) Ramachary, D. B.; Jain, S. *Org. Biomol. Chem.*
56
57
58
59
60

1
2
3 **2011**, 9, 1277. (d) Grondal, C.; Jeanty, M.; Enders, D. *Nat. Chem.* **2010**, 2, 167. (e) Alba, A.-N.;
4 Companyo, X.; Viciano, M.; Rios, R. *Curr. Org. Chem.* **2009**, 13, 1432. (f) Yu, X.; Wang, W.
5
6 *Org. Biomol. Chem.* **2008**, 6, 2037. (g) Enders, D.; Grondahl, C.; Hüttl, M. R. M. *Angew. Chem.,*
7
8 *Int. Ed.* **2007**, 46, 1570.
9

10
11
12
13 (3) For selected examples, see: (a) *The Chemistry of the Quinonoid Compounds*, Vol. 2, Parts 1
14 and 2; Patai, S.; Rappoport, Z. Eds.; Wiley: New York, 1988. (b) *Progress in the Chemistry of*
15 *Quinoidal Natural Products*, Lumb, J.-P. G. ProQuest, 2008. (c) Powis, G. *Pharmac. Ther.* **1987**,
16 35, 57. (d) Gu, J.-Q.; Graf, T. N.; Lee, D.; Chai, H.-B.; Mi, Q.; Kardono, L. B. S.; Setyowati, F.
17 M.; Ismail, R.; Riswan, S.; Farnsworth, N. R.; Cordell, G. A.; Pezzuto, J. M.; Swanson, S. M.;
18 Kroll, D. J.; Falkinham, J. O. III.; Wall, M. E.; Wani, M. C.; Kinghorn, A. D.; Oberlies, N. H. *J.*
19 *Nat. Prod.* **2004**, 67, 1156. (e) Gu, W.; Ge, H. M.; Song, Y. C.; Ding, H.; Zhu, H. L.; Zhao, X.
20 A.; Tan, R. X. *J. Nat. Prod.* **2007**, 70, 114. (f) Luo, J.-G.; Wang, X.-B.; Xu, Y.-M.; U'Ren, J. M.;
21 Arnold, A. E.; Kong, L.-Y.; Gunatilaka, A. A. L. *Org. Lett.* **2014**, 16, 5944. (g) Widhalm, J. R.;
22 Rhodes, D. *Hortic Res.* **2016**, 3, 16046.
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 (4) For selected examples, see: (a) Wellington, K. D.; Cambie, R. C.; Ruteledge, P. S.; Bergquist,
38 P. R. *J. Nat. Prod.* **2000**, 63, 79. (b) Nicolaou, K. C.; Gray, D.; Tae, J. *Angew. Chem., Int. Ed.*
39 **2001**, 40, 3675. (c) Nicolaou, K. C.; Gray, D.; Tae, J. *Angew. Chem., Int. Ed.* **2001**, 40, 3679. (d)
40 Nicolaou, K. C.; Gray, D. L. F.; Tae, J. *J. Am. Chem. Soc.* **2004**, 126, 613. (e) Trost, B. M.;
41 Pissot-Soldermann, C.; Chen, I.; Schroeder, G. M. *J. Am. Chem. Soc.* **2004**, 126, 4480. (f)
42 Mukherejee, H.; McDougal, N. T.; Virgil, S. C.; Stoltz, B. M. *Org. Lett.* **2011**, 13, 825. (g)
43 Singh, A. J.; Dattelbaum, J. D.; Field, J. J.; Smart, Z.; Woolly, E. F.; Barber, J. M.; Heathcott, R.;
44 Miller, J. H.; Northcote, P. T. *Org. Biomol. Chem.* **2013**, 11, 8041.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (5) For a review, see: Zhang, X.; Chen, Y.-H.; Tan, B. *Tetrahedron Lett.* **2018**, *59*, 473. For
4 examples, see: (b) Alemán, J.; Richter, B.; Jørgensen, K. A. *Angew. Chem., Int. Ed.* **2007**, *46*,
5 5515. (c) Alemán, J.; Cabrera, S.; Maerten, E.; Overgaard, J.; Jørgensen, K. A. *Angew. Chem.,*
6 *Int. Ed.* **2007**, *46*, 5520. (d) Alemán, J.; Jacobsen, C. B.; Frisch, K.; Overgaard, J.; Jørgensen, K.
7 A. *Chem. Commun.* **2008**, 632. (e) He, Z.; Liu, T.; Tao, H.; Wang, C.-J. *Org. Lett.* **2012**, *14*,
8 6230. (f) Albrecht, Ł.; Gómez, C. V.; Jacobsen, C. B.; Jørgensen, K. A. *Org. Lett.* **2013**, *15*,
9 3010. (g) Johansen, T. K.; Gómez, C. V.; Bak, J. R.; Davis, R. L.; Jørgensen, K. A. *Chem. Eur.*
10 *J.* **2013**, *19*, 16518. (h) Martín-Santos, C.; Jarava-Barrera, C.; delPozo, S.; Parra, A.; Díaz-
11 Tendero, S.; Mas-Ballesté, R.; Cabrera, S.; Alemán, J. *Angew. Chem., Int. Ed.* **2014**, *53*, 8184. (i)
12 Blom, J.; Johansen, T. K.; Jensen, F.; Jørgensen, K. A. *Chem. Commun.* **2016**, *52*, 7153.

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27 (6) For selected reviews, see: (a) Fuson, R. C. *Chem. Rev.* **1935**, *16*, 1. (b) Casiraghi, G.;
28 Battistini, L.; Curti, C.; Rassu, G.; Zanardi, F. *Chem. Rev.* **2011**, *111*, 3076. (c) Pansare, S. V.;
29 Paul, E. K. *Chem. Eur. J.* **2011**, *17*, 8770. (d) Bisai, V. *Synthesis* **2012**, *44*, 1453. (e) Jusseau, X.;
30 Chabaud, L.; Guillou, C. *Tetrahedron* **2014**, *70*, 2595. (f) Kalesse, M.; Cordes, M.; Symkenberg,
31 G.; Lu, H.-H. *Nat. Prod. Rep.* **2014**, *31*, 563. (g) Schneider, C.; Abels, F. *Org. Biomol. Chem.*
32 **2014**, *12*, 3531.

33
34
35
36
37
38
39
40
41
42 (7) (a) Jiang, H.; Albrecht, Ł.; Jørgensen, K. A. *Chem. Sci.* **2013**, *4*, 2287. (b) Jurberg, I. D.;
43 Chatterjee, I.; Tannert, R.; Melchiorre, P. *Chem. Commun.* **2013**, *49*, 4869. (c) Hepburn, H. B.;
44 Dell'Amico, L.; Melchiorre, P. *Chem. Rec.* **2016**, *16*, 1787. (d) Battistini, L.; Curti, C.; Rassu, G.;
45 Sartori, A.; Zanardi, F. *Synthesis* **2017**, *49*, 2297. (e) Chauhan, P.; Kaya, U.; Enders, D. *Adv.*
46 *Synth. Catal.* **2017**, *359*, 888. (f) Yin, Y.; Jiang, Z. *ChemCatChem* **2017**, *9*, 4306.

1
2
3 (8) For selected reviews on organocatalysis, see: (a) Bella, M.; Gasperi, T. *Synthesis* **2009**,
4 1583. (b) Palomo, C.; Oiarbide, M.; López, R. *Chem. Soc. Rev.* **2009**, 38, 632. (c) Melchiorre, P.
5
6
7 *Angew. Chem., Int. Ed.* **2012**, 51, 9748. (d) Albrecht, Ł.; Jiang, H.; Jørgensen, K. A. *Chem. Eur.*
8
9 *J.* **2014**, 20, 358. (e) Alemán, J.; Cabrera, S. *Chem. Soc. Rev.* **2013**, 42, 774.

10
11
12
13 (9) For seminal reports, see: (a) Marigo, M.; Wabnitz, T. C.; Fielenbach, D.; Jørgensen, K. A.
14
15 *Angew. Chem., Int. Ed.* **2005**, 44, 794. (b) Marigo, M.; Fielenbach, D.; Braunton, A.;
16
17 Kjærsgaard, A.; Jørgensen, K. A. *Angew. Chem., Int. Ed.* **2005**, 44, 3703. (c) Hayashi, Y.; Gotoh,
18
19 H.; Hayashi, T.; Shoji, M. *Angew. Chem., Int. Ed.* **2005**, 44, 4212; for selected reviews, see: (d)
20
21 Jensen, K. L.; Dickmeiss, G.; Jiang, H.; Albrecht, Ł.; Jørgensen, K. A. *Acc. Chem. Res.* **2012**, 45,
22
23 248. (e) Donslund, B. S.; Johansen, T. K.; Poulsen, P. H.; Halskov, K. S.; Jørgensen, K. A.
24
25
26 *Angew. Chem., Int. Ed.* **2015**, 54, 13860.

27
28
29
30 (10) CCDC 1587384 contains the supplementary crystallographic data for this paper. These data
31
32 can be obtained free of charge from The Cambridge Crystallographic Data Centre via
33
34 www.ccdc.cam.ac.uk/data_request/cif.

35
36
37
38 (11) (a) Pluim, H.; Wynberg, H. *J. Org. Chem.* **1980**, 45, 2498. (b) Bunge, A.; Hamann, H.-J.;
39
40 McCalmont, E.; Liebscher, J. *Tetrahedron Lett.* **2009**, 50, 4629.

41
42
43
44 (12) Daubresse; N.; Francesch; C.; Rolando, C. *Tetrahedron*, **1998**, 54, 10761.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60